DISEASE INDICATIONS: Acquired thrombotic thrombocytopenic purpura (aTTP)
MANUFACTURER: Ablynx NV
USAGE: Intravenous
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Health Canada
Therapeutic Goods Administration (TGA)
Cablivi, with its active ingredient caplacizumab, is a prescription medication used in the treatment of a rare and serious medical condition known as acquired thrombotic thrombocytopenic purpura (aTTP).
